공시 • Apr 02
Avenir Wellness Solutions, Inc. announced delayed annual 10-K filing On 04/01/2025, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Nov 16
Avenir Wellness Solutions, Inc. announced delayed 10-Q filing On 11/15/2024, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • May 18
Avenir Wellness Solutions, Inc. announced delayed 10-Q filing On 05/16/2024, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Apr 02
Avenir Wellness Solutions, Inc. announced delayed annual 10-K filing On 04/01/2024, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Aug 17
Avenir Wellness Solutions, Inc. Provides Sales Guidance for the Second Half of 2023 Avenir Wellness Solutions, Inc. provided sales guidance for the second half of 2023. For the period, sales are expected to increase. New Risk • Jun 10
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.68m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$10m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$173k). Earnings have declined by 17% per year over the past 5 years. Market cap is less than US$10m (US$9.68m market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (11% increase in shares outstanding). 공시 • May 16
Avenir Wellness Solutions, Inc. announced delayed 10-Q filing On 05/15/2023, Avenir Wellness Solutions, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Jan 20
Avenir Wellness Solutions to Launch Wall Street-Focused Informational Series with Producer New to the Street Avenir Wellness Solutions, Inc. announced that it is launching an informational series to inform the Wall Street community about its unique dual revenue model involving breakthrough consumer wellness products and intellectual property monetization. Avenir has retained producer New to The Street to create sponsored television content featuring Avenir's leadership that will be nationally and internationally syndicated on major television networks. Avenir's management will introduce themselves to New to The Street's viewers and provide updates about the Company's science-based delivery systems for their wellness, skincare/beauty, and new market disruptive products. Filmed discussions will occur at the on-site studios, New York Stock Exchange,Nasdaq MarketSite, or off-site through Zoom video calls. Each segment is to air across New to The Street's syndicated televised platforms on Newsmax TV and FOX Business Network, and as a sponsored program on Bloomberg TV. New to The Street expects each televised airing to bring attention to Avenir's operations and how they are developing new cutting-edge technologies and building the foundation of the Company. Avenir has uniquely positioned itself to enhance its market share within its multi-billion-dollar industry. 공시 • Nov 15
CURE Pharmaceutical Holding Corp. announced delayed 10-Q filing On 11/14/2022, CURE Pharmaceutical Holding Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Aug 03
CURE Pharmaceutical Holding Corp. Appoints Gerald Bagg to Its Board of Directors CURE Pharmaceutical Holding Corp. announced the appointment of Gerald Bagg to its board of directors. This strategic addition adds depth in CPG and advertising and brings the number of board members to five. A 45+ year veteran of the advertising industry, Gerald is best known for pioneering the BRAND RESPONSE advertising approach to campaigns. Gerald is the Chairman and a co-founder of Quigley-Simpson & Heppelwhite Inc. Prior to establishing Quigley-Simpson, Gerald had an extensive advertising and marketing career beginning in 1976. Gerald’s distinguished career has included senior executive positions with major advertising agencies and retailers. 공시 • Apr 03
CURE Pharmaceutical Holding Corp. announced delayed annual 10-K filing On 04/01/2022, CURE Pharmaceutical Holding Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Mar 05
CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico Cure Pharmaceutical and Milagro Pharmaceuticals announced their collaboration to register and sell in Mexico a number of CURE’s OTC and medical compounds that utilize CUREform, CURE’s patented drug delivery platform for oral thin film. Cure is in discussions with several large distributors in Mexico and Latin America. OTF products that will be marketed and sold in Mexico via key distribution partners include CUREfilm Blue - an oral soluble form of sildenafil citrate for the treatment of erectile dysfunction. Vitamin D3 - that provides a convenient, weekly 40,000 IU dose of Vitamin D An electrolyte energy boost - that provides a healthier, sugar-free alternative to energy drinks Sleep - a dose of melatonin that dissolves on the tongue so it can be taken even after the user climb into bed. The opportunity to serve the Latin American market with this venture into Mexico is an exciting one that is expected to accelerate the ramp up of CURE’s FDA-registered, cGMP manufacturing facility, where the Company pioneered and developed its patented CUREfilm, drug delivery platform. The Company expects to select a distribution partner for the LATAM territory in the coming months. 공시 • Mar 17
CURE Pharmaceutical Holding Corp. Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders CURE Pharmaceutical Holding Corp. announced that it has launched a new initiative for the clinical development of psychedelic compounds such as psilocybin, LSD, and MDMA for the treatment of various mental health disorders. Utilizing CURE’s patented oral film platform CUREfilm for precision dosing, the company intends to optimize the absorption and metabolism of psychedelic actives targeting clinical efficacy of both macrodosing and microdosing treatment regimens. CURE will use its DEA Schedule 1 license and cGMP-certified and FDA-registered facility providing a United States footprint for anticipated commercialization. Ongoing research, which has been active for decades, continues to showcase a growing body of evidence in support of psychedelics as effective treatments for mental health disorders such as depression, PTSD, addiction disorders, obsessive compulsive disorder, and anxiety. 공시 • Mar 12
CURE Pharmaceutical Holding Corp. Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications CURE Pharmaceutical Holding Corp. announced that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline. The first is an antiviral clinical development program where the Company will look to load a known active pharmaceutical ingredient (API) onto its patented drug delivery platform CUREfilm®, CURE’s oral thin film platform that optimizes the absorption and metabolism of therapeutic actives. The second pipeline product addition uses a similar bioequivalence approach where the Company will formulate the delivery of a known anti-seizure API for both adult and pediatric indications. These programs will leverage existing pre-clinical/clinical safety and toxicity data to develop orally bioavailable products and expand the Company’s pharmaceutical research & development efforts toward building a specialty pharmaceutical pipeline. CURE recently announced the start of its initial Pharmacokinetics (PK)/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Sildenafil Citrate oral dispersible product known as CUREfilm® blue. This application, as well as these additional pipeline products are anticipated to be initiated via the 505(b)(2) drug approval pathway, with both Academic and Industry partnerships anticipated to facilitate the most intuitive path to commercialization. 공시 • Feb 24
CURE Pharmaceutical Announces the Initiation of Clinical Trials for Erectile Dysfunction Product Curefilm Blue™ CURE Pharmaceutical Holding Corp. announced this week’s start of its initial Pharmacokinetics (PK)/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). This application has been initiated via the 505(b)(2) drug approval pathway, and is in continuation of FDA-provided feedback in support of CURE’s clinical development plans for its CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED). CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience. The global erectile dysfunction drug market is projected to reach approximately $6.6 Billion by 2025, at a CAGR of 6.0% over the five-year forecasted period with sildenafil representing a majority of the market
according to a report by QYR Research. 공시 • Feb 12
CURE Pharmaceutical Holdings Announces Promotions and Additions to Board of Directors CURE Pharmaceutical Holdings announced updates and additions to its Board of Directors. After a dedicated run as Chairman of the Board, William Yuan is stepping down and will continue to serve the Company as an advisor and Chairman Emeritus. Rubén José King-Shaw Jr, a highly qualified and respected member of the Board, has been selected to step into that role. Mr. King-Shaw brings with him three decades of executive leadership experience in the healthcare technology and private equity sectors. He recently served on the board of Atlanta-based Cotiviti Holdings Inc. and currently serves on the board of US Retina of Denver, CO. He is currently serving as Chief Strategy Officer of Steward Health Care Systems, LLC, and has held C-suite positions with leading private companies including Neighborhood Health Partnership Inc. and JMH Health Plan. 공시 • Jan 06
Cure Pharmaceutical Receives Fda Approval for Its Ind Application for Erectile Dysfunction Product Curefilm Blue™ CURE Pharmaceutical Holding Corp. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience. 공시 • Oct 30
CURE Pharmaceutical Holding Corp. Appoints Nancy Duitch to the Board Effective October 23, 2020, the Board of Directors of Cure Pharmaceutical Holding Corp. (the “Company”), appointed Nancy Duitch as a new member of the Board pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 23, 2020 (the “Merger Agreement”), by and among the Company, Cure Labs Inc., and The Sera Labs Inc., and Nancy Duitch, in her capacity as the security holders representative. On October 5, 2020, as a condition to closing the Merger, the Company entered into an employment agreement with Ms. Duitch as Chief Strategy Officer-Wellness of the Company. 공시 • Oct 01
CURE Pharmaceutical Holding Corp. announced that it has received $1 million in funding from Ionic Ventures, LLC CURE Pharmaceutical Holding Corp. (OTCPK:CURR) announced a private placement of demand secured promissory note for principal amount of $1,100,000 receiving gross proceeds of $1,000,000 on September 25, 2020. The transaction included participation from Ionic Ventures, LLC. The promissory note are issued at $100,000 original discount. The notes bears no interest rate and is subject to payment on demand of the investor after the earlier of either the initial date after September 25, 2020 of any offering of securities by the company with gross proceeds of at least $1,000,000 or October 31, 2020. 공시 • Sep 30
Cure Pharmaceutical Holding Corp. to Enter into an Employment Agreement with Nancy Duitch in Her Capacity as Chief Strategy Officer - Wellness On September 23, 2020, Cure Pharmaceutical Holding Corp. (the “Company”) entered into an Agreement and Plan of Merger and Reorganization by and among the Company, Cure Labs Inc., a Delaware corporation and a wholly owned, subsidiary of the Company (“Merger Sub”), The Sera Labs Inc., a Delaware corporation (“Sera Labs”), and Nancy Duitch, in her capacity as the security holders representative. The Merger Agreement provides for the acquisition of Sera Labs by the Company through the merger of Merger Sub with and into Sera Labs, with Sera Labs surviving as a wholly owned, subsidiary of the Company (the “Merger”). The Merger Agreement also contemplates that at the Effective Time the Company will enter into an employment agreement with Nancy Duitch in her capacity as Chief Strategy Officer - Wellness of the Company and Chief Executive Officer of Sera Labs. 공시 • Sep 26
Cure Pharmaceutical Holding Corp. Announces Appointments to its Board Cure Pharmaceutical Holding Corp. at its AGM held on September 23, 2020 announced appointment of Gene Salkind and Lauren Chung to the Board of Directors, each for a one-year term ending at the Annual Meeting of Stockholders to be held in 2021 and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. 